Advertisement

Breast Cancer Research

, 13:406 | Cite as

Erratum to: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer

  • Andrea H Bild
  • Joel S Parker
  • Adam M Gustafson
  • Chaitanya R Acharya
  • Katherine A Hoadley
  • Carey Anders
  • P Kelly Marcom
  • Lisa A Carey
  • Anil Potti
  • Joseph R Nevins
  • Charles M Perou
Erratum

In our previous publication [1], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [2, 3]). It has recently been determined that the chemotherapy-response signatures in [2] are not reproducible, causing retraction of that article [3]. As such, the results presented in Figure 4 of our original paper [1] are no longer valid.

We believe that the data presented in Figures 1, 2, 3 of our article remain valid. However, as Figure 4 can no longer be considered valid, portions of [1] are no longer applicable, including the Materials and Methods section entitled "Chemosensitivity signatures", the Results section entitled "Genomic signatures that predict response to cytotoxic chemotherapeutics", and other statements in the Abstract, Introduction, Results, Discussion, and Conclusions sections that refer directly or indirectly to the integration of chemotherapy-response signatures into the analytical approach presented in the manuscript. As such, the focus of the manuscript on the utility of an integrated approach using three complementary strategies for gene expression analysis (i.e. breast cancer intrinsic subtype analysis, pathway prediction and chemotherapy-response signatures) should now be interpreted as referring exclusively to the integration of two complementary strategies.

Notes

References

  1. 1.
    Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res. 2009, 11: R55-10.1186/bcr2344.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006, 12: 1294-1300. 10.1038/nm1491.CrossRefPubMedGoogle Scholar
  3. 3.
    Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR: Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2011, 17: 135-10.1038/nm0111-135.CrossRefPubMedGoogle Scholar

Copyright information

© BioMed Central Ltd 2011

Authors and Affiliations

  • Andrea H Bild
    • 1
    • 2
  • Joel S Parker
    • 3
    • 4
  • Adam M Gustafson
    • 5
  • Chaitanya R Acharya
    • 2
  • Katherine A Hoadley
    • 3
    • 4
  • Carey Anders
    • 2
  • P Kelly Marcom
    • 2
  • Lisa A Carey
    • 3
    • 7
  • Anil Potti
    • 2
  • Joseph R Nevins
    • 2
  • Charles M Perou
    • 3
    • 4
    • 6
    • 8
  1. 1.Department of Pharmacology and ToxicologyUniversity of UtahSalt Lake CityUSA
  2. 2.Duke Institute for Genome Sciences & PolicyDuke University Medical CenterDurhamUSA
  3. 3.Lineberger Comprehensive Cancer CenterUniversity of North CarolinaChapel HillUSA
  4. 4.Department of GeneticsUniversity of North CarolinaChapel HillUSA
  5. 5.The Pulmonary CenterBoston University School of MedicineBostonUSA
  6. 6.Department of Pathology & Laboratory MedicineUniversity of North CarolinaChapel HillUSA
  7. 7.Division of Hematology/Oncology, Department of MedicineUniversity of North CarolinaChapel HillUSA
  8. 8.Carolina Center for Genome SciencesUniversity of North CarolinaChapel HillUSA

Personalised recommendations